Use of Dual-Point Fluorodeoxyglucose Imaging to Enhance Sensitivity and Specificity

Seminars in Nuclear Medicine - Tập 42 - Trang 267-280 - 2012
Orazio Schillaci1,2
1Department of Biopathology and Diagnostic Imaging, University “Tor Vergata”, Rome, Italy
2IRCCS Neuromed, Pozzilli, Italy

Tài liệu tham khảo

Langer, 2010, A systematic review of PET and PET/CT in oncology: A way to personalize cancer treatment in a cost-effective manner?, BMC Health Serv Res, 10, 283, 10.1186/1472-6963-10-283

Saif, 2010, Role and cost effectiveness of PET/CT in management of patients with cancer, Yale J Biol Med, 83, 53

Hillner, 2008, Relationship between cancer type and impact of PET and PET/CT on intended management: Findings of the national oncologic PET registry, J Nucl Med, 49, 1928, 10.2967/jnumed.108.056713

Rice, 2011, The next generation of positron emission tomography radiopharmaceuticals in oncology, Semin Nucl Med, 41, 265, 10.1053/j.semnuclmed.2011.02.002

Pauwels, 1998, FDG accumulation and tumor biology, Nucl Med Biol, 25, 317, 10.1016/S0969-8051(97)00226-6

Love, 2005, FDG-PET of infection and inflammation, Radiographics, 25, 1357, 10.1148/rg.255045122

Schillaci, 2009, Hybrid imaging systems in the diagnosis of osteomyelitis and prosthetic joint infection, Q J Nucl Med Mol Imaging, 53, 95

Metser, 2007, Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): Accumulated data from four years of experience with PET/CT, Semin Nucl Med, 37, 206, 10.1053/j.semnuclmed.2007.01.001

Strauss, 1996, Fluorine-18 deoxyglucose and false-positive results: A major problem in the diagnostics of oncological patients, Eur J Nucl Med, 23, 1409, 10.1007/BF01367602

Zhuang, 2001, Dual time point 18F-FDG-PET imaging for differentiating malignant from inflammatory processes, J Nucl Med, 42, 1412

Lowe, 1997, Pulmonary abnormalities and PET data analysis: A retrospective study, Radiology, 202, 435, 10.1148/radiology.202.2.9015070

Nguyen, 2011, Is there a common SUV threshold in oncological FDG-PET/CT, at least for some common indications?, Acta Oncol, 50, 670, 10.3109/0284186X.2010.550933

Fischman, 1993, FDG-PET in oncology: There's more to it than looking at pictures, J Nucl Med, 34, 6

Hamberg, 1994, The dose uptake ratio as an index of glucose metabolism: Useful parameter or oversimplification?, J Nucl Med, 35, 1308

Yamada, 1995, High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue, J Nucl Med, 36, 1301

Lodge, 1999, A PET study of 18FDG uptake in soft tissue masses, Eur J Nucl Med, 26, 22, 10.1007/s002590050355

Boerner, 1999, Optimal scan time for fluorine-18 fluorodeoxyglucose positron emission tomography in breast cancer, Eur J Nucl Med, 26, 226, 10.1007/s002590050381

Hustinx, 1999, Dual time point fluorine-18 fluorodeoxyglucose positron emission tomography: A potential method to differentiate malignancy from inflammation and normal tissue in the head and neck, Eur J Nucl Med, 26, 1345, 10.1007/s002590050593

Nakamoto, 2000, Delayed (18)F-fluoro-2-deoxy-D-glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas, Cancer, 89, 2547, 10.1002/1097-0142(20001215)89:12<2547::AID-CNCR5>3.0.CO;2-V

Kubota, 2001, Advantage of delayed whole-body FDG-PET imaging for tumour detection, Eur J Nucl Med, 28, 696, 10.1007/s002590100537

Higashi, 2002, Relationship between retention index in dual-phase (18)F-FDG-PET, and hexokinase-II and glucose transporter-1 expression in pancreatic cancer, J Nucl Med, 43, 173

Basu, 2007, Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: Should these be routinely employed in assessing patients with cancer?, Eur J Nucl Med Mol Imaging, 34, 1527, 10.1007/s00259-007-0467-5

Gallagher, 1978, Metabolic trapping as a principle of radiopharmaceutical design: Some factors responsible for the biodistribution of [18F] 2-deoxy-2-fluoro-d-glucose, J Nucl Med, 19, 1154

Nelson, 1996, The interaction among glucose transport, hexokinase, and glucose-6-phosphatase with respect to 3H-2-deoxyglucose retention in murine tumor models, Nucl Med Biol, 23, 533, 10.1016/0969-8051(96)00037-6

Vansteenkiste, 2006, PET scan in lung cancer: Current recommendations and innovation, J Thorac Oncol, 1, 71, 10.1016/S1556-0864(15)31516-1

Ung, 2007, 18Fluorodeoxyglucose positron emission tomography in the diagnosis and staging of lung cancer: A systematic review, J Natl Cancer Inst, 99, 1753, 10.1093/jnci/djm232

Gould, 2001, Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: A meta-analysis, JAMA, 21, 914, 10.1001/jama.285.7.914

Matthies, 2002, Dual time point 18F-FDG-PET for the evaluation of pulmonary nodules, J Nucl Med, 43, 871

Alkhawaldeh, 2008, Impact of dual-time-point (18)F-FDG-PET imaging and partial volume correction in the assessment of solitary pulmonary nodules, Eur J Nucl Med Mol Imaging, 35, 246, 10.1007/s00259-007-0584-1

Lubberink, 2002, 110mIn-DTPA-d-Phe1-octreotide for imaging of neuroendocrine tumours with PET, J Nucl Med, 43, 1391

Schillaci, 2009, Accuracy of early and delayed FDG-PET-CT and of contrast-enhanced CT in the evaluation of lung nodules: A preliminary study on 30 patients, Radiol Med, 114, 890, 10.1007/s11547-009-0400-z

MacDonald, 2011, The role of dual time point FDG-PET imaging in the evaluation of solitary pulmonary nodules with an initial standard uptake value less than 2.5, Clin Radiol, 66, 244, 10.1016/j.crad.2010.10.008

Xiu, 2007, Dual-time point FDG-PET imaging in the evaluation of pulmonary nodules with minimally increased metabolic activity, Clin Nucl Med, 32, 101, 10.1097/01.rlu.0000252457.54929.b7

Chen, 2008, Dual-phase 18F-FDG-PET in the diagnosis of pulmonary nodules with an initial standard uptake value less than 2.5, Am J Roentgenol, 191, 475, 10.2214/AJR.07.3457

Barger, 2012, Diagnostic performance of dual-time 18F-FDG-PET in the diagnosis of pulmonary nodules: A meta-analysis, Acad Radiol, 19, 153, 10.1016/j.acra.2011.10.009

Laffon, 2009, Assessment of dual-time-point 18F-FDG-PET imaging for pulmonary lesions, Nucl Med Commun, 30, 455, 10.1097/MNM.0b013e32832bdcac

Cloran, 2010, Limitations of dual time point PET in the assessment of lung nodules with low FDG avidity, Lung Cancer, 68, 66, 10.1016/j.lungcan.2009.05.013

Lan, 2008, The value of dual time point (18)F-FDG-PET imaging for the differentiation between malignant and benign lesions, Clin Radiol, 63, 756, 10.1016/j.crad.2008.01.003

Núñez, 2007, Improvement in sensitivity with delayed imaging of pulmonary lesions with FDG-PET, Rev Esp Med Nucl, 26, 196, 10.1157/13107971

Suga, 2009, Dual-time point 18F-FDG-PET/CT scan for differentiation between 18F-FDG avid non-small cell lung cancer and benign lesions, Ann Nucl Med, 23, 427, 10.1007/s12149-009-0260-6

Uesaka, 2008, Evaluation of dual-time-point 18F-FDG-PET for staging in patients with lung cancer, J Nucl Med, 49, 10.2967/jnumed.108.051250

Shinya, 2009, Dual-time-point F-18 FDG-PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer, Clin Nucl Med, 34, 216, 10.1097/RLU.0b013e31819a1f3d

Kim, 2011, Limited predictive value of dual-time-point F-18 FDG-PET/CT for evaluation of pathologic N1 status in NSCLC patients, Clin Nucl Med, 36, 434, 10.1097/RLU.0b013e31820adef8

Yen, 2008, 18F-FDG-PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: Is dual time point imaging worth the effort?, Eur J Nucl Med Mol Imaging, 35, 1305, 10.1007/s00259-008-0733-1

Kasai, 2010, Dual-time point scanning of integrated FDG-PET/CT for the evaluation of mediastinal and hilar lymph nodes in non-small cell lung cancer diagnosed as operable by contrast-enhanced CT, Eur J Radiol, 75, 143, 10.1016/j.ejrad.2009.04.044

Li, 2011, Regional nodal staging with (18)F-FDG-PET-CT in non-small cell lung cancer: Additional diagnostic value of CT attenuation and dual-time-point imaging, Eur J Radiol

Hu, 2011, Value of dual-time-point FDG-PET/CT for mediastinal nodal staging in non-small-cell lung cancer patients with lung comorbidity, Clin Nucl Med, 36, 429, 10.1097/RLU.0b013e3182173810

Alkhawaldeh, 2011, Impact of dual-time-point F-18 FDG-PET/CT in the assessment of pleural effusion in patients with non-small-cell lung cancer, Clin Nucl Med, 36, 423, 10.1097/RLU.0b013e3182173823

Houseni, 2010, Prognostic implication of dual-phase PET in adenocarcinoma of the lung, J Nucl Med, 51, 535, 10.2967/jnumed.109.068643

Kim, 2011, Limited prognostic value of dual time point F-18 FDG-PET/CT in patients with early stage (stage I & II) non-small cell lung cancer (NSCLC), Radiother Oncol, 98, 105, 10.1016/j.radonc.2010.11.007

Beaulieu, 2003, SUV varies with time after injection in (18)F-FDG-PET of breast cancer: Characterization and method to adjust for time differences, J Nucl Med, 44, 1044

Kumar, 2005, Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG-PET, J Nucl Med, 46, 1819

Mavi, 2006, Dual time point 18F-FDG-PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes, J Nucl Med, 47, 1440

Caprio, 2010, Dual-time-point [18F]-FDG-PET/CT in the diagnostic evaluation of suspicious breast lesions, Radiol Med, 115, 215, 10.1007/s11547-009-0491-6

Zytoon, 2009, Breast cancer with low FDG uptake: Characterization by means of dual-time point FDG-PET/CT, Eur J Radiol, 70, 530, 10.1016/j.ejrad.2008.01.045

Choi, 2011, The value of dual-time-point 18F-FDG-PET/CT for identifying axillary lymph node metastasis in breast cancer patients, Br J Radiol, 84, 593, 10.1259/bjr/56324742

Arena, 2008, Dual-phase FDG-PET: Delayed acquisition improves hepatic detectability of pathological uptake, Radiol Med, 113, 875, 10.1007/s11547-008-0287-0

Lee, 2011, Detection of hepatic metastases using dual-time-point FDG-PET/CT scans in patients with colorectal cancer, Mol Imaging Biol, 13, 565, 10.1007/s11307-010-0394-x

Kitapci, 2010, FDG-PET/CT in the evaluation of epithelioid hemangioendothelioma of the liver: The role of dual-time-point imaging, Ann Nucl Med, 24, 549, 10.1007/s12149-010-0379-5

Nishiyama, 2006, Dual-time-point 18F-FDG-PET for the evaluation of gallbladder carcinoma, J Nucl Med, 47, 633

Shum, 2011, Clinical usefulness of dual-time FDG-PET–CT in assessment of esophageal squamous cell carcinoma, Eur J Radiol

Okano, 2011, 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of small pancreatic cancer, World J Gastroenterol, 17, 231, 10.3748/wjg.v17.i2.231

Lyshchik, 2005, Dual-phase 18F-fluoro-2-deoxy-d-glucose positron emission tomography as a prognostic parameter in patients with pancreatic cancer, Eur J Nucl Med Mol Imaging, 32, 389, 10.1007/s00259-004-1656-0

Toriihara, 2011, Normal variants of bowel FDG uptake in dual-time-point PET/CT imaging, Ann Nucl Med, 25, 173, 10.1007/s12149-010-0439-x

Yen, 2003, Value of dual-phase 2-fluoro-2-deoxy-d-glucose positron emission tomography in cervical cancer, J Clin Oncol, 21, 3651, 10.1200/JCO.2003.01.102

Lai, 2004, Restaging of recurrent cervical carcinoma with dual-phase [18F]fluoro-2-deoxy-d-glucose positron emission tomography, Cancer, 100, 544, 10.1002/cncr.11928

Ma, 2003, Delayed 18F-FDG-PET for detection of paraaortic lymph node metastases in cervical cancer patients, J Nucl Med, 44, 1775

Kim, 2010, The efficacy of dual time point F-18 FDG-PET imaging for grading of brain tumors, Clin Nucl Med, 35, 400, 10.1097/RLU.0b013e3181db4cfb

Prieto, 2011, Voxel-based analysis of dual-time-point 18F-FDG-PET images for brain tumor identification and delineation, J Nucl Med, 52, 865, 10.2967/jnumed.110.085324

Horky, 2011, Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis, J Neuro Oncol, 103, 137, 10.1007/s11060-010-0365-8

Spence, 2004, 18F-FDG-PET of gliomas at delayed intervals: Improved distinction between tumor and normal gray matter, J Nucl Med, 45, 1653

Chen, 2010, Exposing the evil in the dark: The usefulness of delayed-phase FDG-PET scan to enhance the detectability of tiny residual skull base osteosarcoma initially concealed by adjacent high physiological brain activity, Clin Nucl Med, 35, 630, 10.1097/RLU.0b013e3181e4dce5

Yen, 2005, Are dual-phase F-18-FDG-PET scans necessary in nasopharyngeal carcinoma to assess the primary tumour and locoregional nodes?, Eur J Nucl Med Mol Imaging, 32, 541, 10.1007/s00259-004-1719-2

Zhuang, 2006, Effect of diazepam on the efficacy of dual-phase FDG-PET imaging, Eur J Nucl Med Mol Imaging, 33, 228, 10.1007/s00259-005-1957-y

Inoue, 2009, (18)F-FDG-PET for the evaluation of thymic epithelial tumors: Correlation with the world Health Organization classification in addition to dual-time-point imaging, Eur J Nucl Med Mol Imaging, 36, 1219, 10.1007/s00259-009-1082-4

Kim, 2011, Limited diagnostic and predictive values of dual-time-point 18F FDG-PET/CT for differentiation of incidentally detected thyroid nodules, Ann Nucl Med, 25, 347, 10.1007/s12149-011-0468-0

Basu, 2009, Positron emission tomography as a diagnostic tool in infection: Present role and future possibilities, Semin Nucl Med, 39, 36, 10.1053/j.semnuclmed.2008.08.004

Cook, 1999, Normal physiological and benign pathological variants of 18-fluoro-2-deoxyglucose positron-emission tomography scanning: Potential for error in interpretation, Semin Nucl Med, 26, 308, 10.1016/S0001-2998(96)80006-7

Lee, 2011, Are we ready for dual-time point FDG-PET imaging?, J Med Imaging Radiat Oncol, 55, 351, 10.1111/j.1754-9485.2011.02296.x

Chan, 2011, Dual-time-point 18F-FDG-PET/CT imaging in the assessment of suspected malignancy, J Med Imaging Radiat Oncol, 55, 379, 10.1111/j.1754-9485.2011.02287.x

Chen, 2008, Optimizing delayed scan time for FDG-PET: Comparison of the early and late delayed scan, Nucl Med Commun, 29, 425, 10.1097/MNM.0b013e3282f4d389

Thông tin
Thông tin xuất bản

Seminars in Nuclear Medicine

Tập 42

267-280

Thông tin tác giả